Sanofi SA reported slightly higher sales in 2016, boosted by income from multiple sclerosis products from Genzyme. But the big event of the year was the completion of a swap with Boehringer Ingelheim enlarging Sanofi's consumer products portfolio. ---Subscribe to MedNous to access this article--- Company News
